The dataset shows a clear leader with 317 records, well ahead of the fifth-place assignee at 53 and the tenth at 34. The leading ten organisations together account for 781 of the 1,039 records in scope, or 75.2%, so filing activity is heavily concentrated rather than evenly spread across the field. A new entrant should expect to be filing into a space where a handful of large biologics companies already hold dense, overlapping claim positions.

Filing peaked at 113 records in 2018 and has eased since, with the most recent complete comparison showing a -35% move from 43 records in 2021 to 28 in 2024. Because patent publication typically lags filing by around 18 months, the 2025 and 2026 figures in any dataset are still incomplete and should not be read as proof the field has gone quiet. The safer read is that activity has cooled from an unusually active 2017-2018 period rather than that interest has disappeared.

Classification data shows C12N (microorganisms and genetic engineering) touching 98.3% of records, while C12M (bioreactor apparatus) sits at 14.2% and C12Q (enzyme and DNA testing methods) at just 2.3%. That gap suggests the instrumentation and in-line assay layer that actually triggers a harvest decision — sensors, real-time viability modelling, integrated titer monitoring — is comparatively open relative to the crowded cell-engineering core. Filers looking for less contested claim space should look at that hardware and assay layer rather than the biology itself.